Corcept Therapeutics Presents Positive Results From Phase 2 Trial Of Relacorilant On Ovarian Cancer
17/9 15:32
(RTTNews) - Corcept Therapeutics Inc. (CORT) said that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer were featured in a proffered paper oral presentation at the...